Please assess the completion status of the following clinical trial:

Trial Title: Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 12 to 24 months on the day of inclusion.~* Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness(es) if required by local regulations).~* Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.~* Toddlers previously included in Study A3L24 who completed the three-dose primary series vaccination of either DTaP-IPV-Hep B-PRP\~T or Infanrix hexa™ at 2,4 and 6 months of age according to protocol (both concomitantly administered with Prevenar™ and Rotarix™).~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the booster vaccinations.~* Planned participation in another clinical trial during the present trial period.~* Receipt of any vaccine in the 4 weeks preceding the booster vaccinations, except in case of pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.~* Planned receipt of any vaccine in the 4 weeks following the trial vaccinations.~* Previous booster vaccination against pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b, hepatitis B and pneumococcal infection(s) with either the trial vaccine or another vaccine.~* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 3 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).~* Laboratory-confirmed or clinical suspicion of personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C, as reported by the parent/guardian.~* History of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b, hepatitis B and pneumococcal infection(s), confirmed either clinically, serologically, or microbiologically.~* At high risk for opportunistic infection during the trial.~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances.~* History of contraindication to receipt of pertussis-containing vaccine.~* Laboratory-confirmed or clinical suspicion of thrombocytopenia contraindicating Intramuscular vaccination.~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.~* History of seizures .~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.~* Receipt of oral or injected antibiotic therapy within 72 hours prior to the first blood draw~* Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Participants previously primed with DTaP-IPV-Hep B-PRP\~T, will receive one dose of DTaP-IPV-Hep B-PRP\~T vaccine + one dose of Prevenar™
- Study Group 2 (Type: ACTIVE_COMPARATOR): Participants previously primed with DTaP-IPV-Hep B-PRP\~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
- Study Group 3 (Type: EXPERIMENTAL): Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP\~T + one dose of Prevenar™.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete